Three-dose Covid-19 vaccine produces strong immune response in young children, Pfizer and BioNTech say
The Phase 2/3 trial included 1,678 children who received a third vaccine dose during the period when the Omicron coronavirus variant dominated. Antibody levels tested one month after the third dose showed that the vaccine produced a similar immune response as two doses in 16- to 25-year-olds, the companies said. The data has not been peer-reviewed or published in a professional journal.
Midtrial results found vaccine efficacy of 80.3% against symptomatic Covid-19 in this young age group. The companies identified 10 symptomatic cases at least seven days after the third dose. However, the efficacy rate won’t be finalized until at least 21 symptomatic cases are found in the vaccine group and compared with the number of symptomatic cases in the placebo group.
The companies said that three child-size doses for this age group were “well-tolerated” and that no new safety signals were identified.
“These topline safety, immunogenicity and efficacy data are encouraging, and we look forward to soon completing our submissions to regulators globally with the hope of making this vaccine available to younger children as quickly as possible, subject to regulatory authorization,” Pfizer Chairman and CEO Albert Bourla said in a statement.
The vaccine doses for these children are smaller than those used in older age groups. People 12 and older receive two doses of a 30-microgram vaccine, and children ages 5 to 12 receive two doses of a 10-microgram vaccine. Both of those age groups are eligible for booster doses.
For children 6 months to 5 years, the Pfizer/BioNTech vaccine is three 3-microgram doses. The initial two doses were given three weeks apart, and the third dose was given at least two months after their second dose.
Dr. William Schaffner, a professor in the Division of Infectious Diseases at Vanderbilt University School of Medicine, said Monday that vaccine scientists have been careful to adjust the dose for younger children to get “a good effect with a minimum of side effects.”
“We’re thinking of this as a three-dose vaccine, and the preliminary data acquired during the Omicron era say it’s actually 80% effective,” Schaffner told CNN’s Brianna Keilar. “We will want to look at that very carefully, but so far, that’s good news.”
In February, the US Food and Drug Administration asked the companies to submit a request for emergency use authorization based on the two-dose data but then postponed a meeting of the agency’s vaccine advisory board so the third-dose data could be considered.